Among the IMIDs, RA has the widest range of biological agents with different modes of action or small molecule inhibitors available for treatment (tumor necrosis factor inhibitors, interleukin-6 receptor inhibitors, co-stimulation inhibitors, anti-B cells, and Janus kinase inhibitors) (63). Here, TNF is linked to rheumatoid arthritis.